U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...